National and Kapodistrian University of Athens
Ο ογκογενετικός ρόλος του σηματοδοτικού μορίου STAT3 στο ακανθοκυτταρικό καρκίνωμα του στόματος
Abstract
dc:descriptionThe oncogenetic role of STAT3 signaling molecule in oral squamous cell carcinoma.Gkouveris IoannisOral cancer is the sixth most common cancer worldwide and the incidence of new cases indicates a continuing rise in developing countries. Several genetic and epigenetic alterations underlie the progressive acquisition of a malignant phenotypein head and neck squamous cell carcinoma (HNSCC). The molecular dissection of aberrant signaling networks, including EGFR, Ras, NF-κB, Wnt/β-catenin, TGF-β, and PI3K-AKT-mTOR signaling pathways, has increased our understanding on the basic mechanisms controlling HNSCC progression.Signal transducer and activator of transcription (STAT) proteins constitute a family of transcription factors, which exist in the cell as latent cytoplasmic transcription factors and become activated in response to stimulation by cytokines and growth factors, translocate to the nucleus, where they interact with the promoters of target genes. Phosphorylation of STAT molecules on a tyrosine residue is the first critical event for their activation and has been convincingly shown to correlate with STAT DNA binding and transcriptional activity. In contrast, STAT serine phosphorylation, which may also occur in response to growth factor and cytokine stimulation, has been associated mainly with negative regulation of STAT activity. STAT signaling has been found to be involved in oncogenesis There is compelling evidence that STAT3 constitutive activation, mainly associated with aberrant TGF-α/EGFR signaling, is linked to HNSCC development and growth.Mitogen-activated protein kinase (MAPK) pathways are evolutionarily conserved kinase modules that link extracellular signals to the machinery that controls fundamental cellular processes such as growth, proliferation, differentiation, migration and apoptosis. MAPKs phosphorylate serine and threonine residues of specific target proteins. They are classified into three major subfamilies, including extracellular signal-regulated kinases (ERKs), p38 MAPKs, and c-Jun NH2-terminal kinases (JNKs) Previous studies supported an association between activation of specific members of the MAPK family and negative regulation of STAT3, manifested by downregulation of STAT3 tyrosine phosphorylation and induction of STAT3 serine phosphorylation, in various cell types including cancer cells. PURPOSEThe aim of the present investigation was to evaluate whether oncogenic constitutive STAT3 signaling in oral squamous cell carcinoma (OSCC) cells can be modulated by regulation of specific MAPKs. The expression and activation status of STAT3 and MAPKs in HNSCC cell lines were recorded and the effects of selective MAPKs inhibition or activation on STAT3 signaling and cellular proliferation were monitored, in an attempt to elucidate important molecular aspects of oral cancer with potential therapeutic implications.MATERIAL AND METHODS Cell lines and cell culture. Experiments were performed using established cell lines of human HNSCC (SCC9 and SCC25) obtained from the American Type Culture Collection (ATCC;Manassas, VA, USA). Selective inhibition of MAPKs. Cells were treated either with the vehicle alone(DMSO) or with the selective MAPK inhibitor (JNK1/2- SP600125, p38-SB203580, Erk1/2-U0126) (Calbiochem, San Diego, CA, USA) at specific concentrations for 24 h.Selective induction of MAPKs. Cells were treated either with the vehicle alone (DMSO) or with the selective MAPK (active Mek1/2-Erk1/2, active MKK7-JNK1/2) inducers (ProSpec, Israel) at specific concentrations for 48 h. siRNA transfection: JNK1, JNK2 and Erk1, Erk2 siRNAs were based on NCBI Reference Sequences (GenBank:Erk1: NM_002746 and Erk2: NM_002745). All siRNA and scrambled control siRNA (siControl) were purchased from Qiagen. All siRNA transfections were performed using Lipofectamine 2000 (Invitrogen), according to the manufacturer's protocol. After OSCC cells were grown, they were transiently transfected with 50 μg of the empty vector or siRNA using Nucleofector II reagents (Amaxa Biosystems-Lonza, Cologne, Germany).Western blot experiments. Western blotting was performed using antibodies against: total STAT3, phospho-STAT3 (Tyr705), phospho-STAT3 (Ser727), total p44/42(Erk1/2) total p38, total JNK1/2, phospho-p38, phospho-c-Jun, cyclin D1 (Cell Signaling, Beverly, MA,USA), phospho-Erk1/2 (Upstate, Charlottesville, VA, USA), cyclin D1 (Cell Signaling) and β-actin (Sigma Chemical).Cell proliferation and viability. Cells were counted with a hemocytometer under inverted microscope. Cell viability after treatment was determined by the trypan blue dye exclusion test 24 h after each treatment. All assays were performed inquadruplicate and results are reported as the mean ± SD.Immunohistochemistry. The material consisted of 60 specimens diagnosed as oral SCC, selected from the Department of Oral Pathology and Medicine, Faculty of Dentistry, University of Athens. The specimens were divided in 3 groups of 20 cases according to their differentiation level (high, medium, poor). Staining was performed for the following antibodies: phospho-STAT3 (Tyr705)(1:100), phospho-STAT3 (Ser727) (1:100), phospho-cJun (1:100), phospho-ERK1/2(1:100), phospho-p38(1:100).Statistical Analysis. The relationship between cell viability/cell number and concentrations of chemical reagents was assessed with the t-test. The association between immunohistochemical variables (intensity/ percentage of positive cells, combined score) and differentiation levels was analyzed by Fisher’s test. Differences were considered to be statistically significant when: p< 0.05.RESULTSThe results of this study are summarized as follows:Erk1/2 inhibition: Erk1/2 inhibition by U0126 treatment was more potent in oral SCC25 cells and was associated with a decrease in p-ser STAT3 and cyclin D1 levels without affecting p-tyr STAT3 levels. Moreover, specific silencing of Erk1/2 resulted in a decrease in p-ser STAT3 and cyclin D1 levels in both cell lines and an increase in p-tyr-STAT3, particularly in oral SCC9 cells. Both chemical inhibition with U0126 and silencing Erk1/2 resulted in a dose-dependent reduction in cell growth and cell viability in both cell lines.Erk1/2 induction: Erk1/2 induction caused upregulation of p-ser STAT3 and cyclin D1 levels in both cell lines, decrease in p-tyr-STAT3 and resulted in a significant dose-dependent increase in cell growth, which was more prominent in the oral SCC25 cell line. On the contrary, treatment of cells with active MEK1/2 did not appear to induce notable changes in cell viability in either cell line.JNK1/2 inhibition: JNK1/2 inhibition by SP600125 treatment was detected in both cell lines and was associated with increases in p-tyrr Stat3 and cyclin D1 levels as well as decreases in p-serr Stat3 levels at the highest concentration used. Specific silencing of JNK1/2 resulted in decreases in p-ser Stat3 and cyclin D1 levels in both cell lines and increases in p-tyr-Stat3 particularly in oral SCC9 cells. Similar to chemical inhibition with SP600125 silencing of JNK1/2 resulted in a dose-dependent rise in cell growth and cell viability in both cell lines. JNK1/2 induction: JNK1/2 induction caused upregulation of p-ser Stat3 levels in both cell lines and decreases in p-tyr Stat3 and cyclin D1. Moreover, active MKK7 treatment at the highest concentration resulted in significant dose-dependent decrease in cell growth and cell viability, which was more prominent in oral SCC25 cell line. P38 inhibition: p38 inhibition by SB203580 treatment was not associated with any significant change in phosphorylated levels of STAT3 (ser/tyr) and cyclin D1 in both cell lines. Furthermore treatment with SB203580 for 24h resulted in no statistically significant changes in cell growth and cell viability in both cell lines tested. Immunohistochemistryp-STAT3(ser): Eventhough poorly differentiated neoplasms showed the lowest mean average score, no statistically significant correlation was found between the three histopathological parameters (intensity/percentage of positive cells, combined score) and differentiation level for p-STAT3(ser). p-STAT3(tyr): Statistically significant correlation (p<0.05) was found between all three histopathological parameters and differentiation level of neoplasms with poorly differentiated cases showing the highest mean average scores. Furthermore statistically significant difference (p<0.05) was found between poorly and well differentiated neoplasms for all tested parameters. p-p38: No statistically significant correlation was found between the three histopathological parameters (intensity/percentage of positive cells, combined score) and differentiation level for p-p38. p-Erk1/2: There is statistically significant correlation (p<0.05) between all three histopathological parameters and differentiation level of neoplasms with poorly differentiated cases showing the highest mean average scores. Moreover statistically significant difference (p<0.05) was found between poorly and well differentiated neoplasms for all the tested parameters. p-cJun: Poorly differentiated neoplasms showed the lowest mean average score for all three histopathological parameters, but the only statistically significant correlation (p<0.05) concerned intensity score between poorly and medium differentiated neoplasms.CONCLUSIONS- Our data are supportive of the oncogenic potential of Erk1/2 in OSCC, which appears to contribute to cell proliferation. - The oncogenic STAT3 constitutive signaling in OSCC cells appears to be negatively regulated by Erk1/2. The Erk1/2-STAT3 crosstalk appears to involve mainly ERK-induced upregulation of STAT3(Ser727) phosphorylation while Tyr705 phosphorylation does not exhibit major changes.- JNK1/2 oncosuppressor potential in OSCC is supported by the reduction of cell proliferation and cell viability.- The oncogenic Stat3 constitutive signaling in OSCC cells is negatively regulated by JNK. The JNK-STAT3 crosstalk seems to respond mostly through the downregulation of Stat3 phosphorylation on Ser727 residue and upregulation of Tyr 705. - P38 does not appear to play a significant role in STAT3 signaling, cell proliferation and cell viability. - ΕRK1/2, p38 and p-cJun are strongly expressed in OSCC indicating their significance in this type of cancer.- It is possible that the role of Erk1/2, JNK and p38 in STAT3 modulation varies according to the type and status of the cells studied, indicating the need to identify the role of MAPK activation in relation to STAT3 signaling in specific cell types. - Understanding MAPK pathway complexity and cross-talk between other major molecules such as STAT3 will be helpful to pharmacologic therapies for cancer prevention.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gkouveris, Ioannis
- Γκούβερης, Ιωάννης
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/35601